

North Central Cancer Treatment Group

N0572: A Phase I/II Study of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma

Status Change Notice – June 3, 2009

**NOTICE OF STATUS CHANGE**

Study 2, Group 1 (Arm B) is temporarily suspended to accrual effective Wednesday, June 3, 2009 to allow for the interim analysis. Patients currently on study should be followed according to the protocol.

**Please retain this notice with the protocol.**